tetano
Editor, Senior Moderator
Cell Rep
. 2021 Oct 8;109882.
doi: 10.1016/j.celrep.2021.109882. Online ahead of print.
Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex
Jiqin Wu[SUP] 1 [/SUP], Haofeng Wang[SUP] 2 [/SUP], Qiaojie Liu[SUP] 1 [/SUP], Rui Li[SUP] 3 [/SUP], Yan Gao[SUP] 4 [/SUP], Xiang Fang[SUP] 3 [/SUP], Yao Zhong[SUP] 3 [/SUP], Meihua Wang[SUP] 3 [/SUP], Quan Wang[SUP] 5 [/SUP], Zihe Rao[SUP] 6 [/SUP], Peng Gong[SUP] 7 [/SUP]
Affiliations
Abstract
Remdesivir (RDV), a nucleotide analog with broad-spectrum features, has exhibited effectiveness in COVID-19 treatment. However, the precise working mechanism of RDV when targeting the viral RNA-dependent RNA polymerase (RdRP) has not been fully elucidated. Here, we solve a 3.0-Å structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RdRP elongation complex (EC) and assess RDV intervention in polymerase elongation phase. Although RDV could induce an "i+3" delayed termination in meta-stable complexes, only pausing and subsequent elongation are observed in the EC. A comparative investigation using an enterovirus RdRP further confirms similar delayed intervention and demonstrates that steric hindrance of the RDV-characteristic 1'-cyano at the -4 position is responsible for the "i+3" intervention, although two representative Flaviviridae RdRPs do not exhibit similar behavior. A comparison of representative viral RdRP catalytic complex structures indicates that the product RNA backbone encounters highly conserved structural elements, highlighting the broad-spectrum intervention potential of 1'-modified nucleotide analogs in anti-RNA virus drug development.
Keywords: RNA-dependent RNA polymerase; SARS-CoV-2; broad-spectrum; elongation complex; remdesivir.
. 2021 Oct 8;109882.
doi: 10.1016/j.celrep.2021.109882. Online ahead of print.
Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex
Jiqin Wu[SUP] 1 [/SUP], Haofeng Wang[SUP] 2 [/SUP], Qiaojie Liu[SUP] 1 [/SUP], Rui Li[SUP] 3 [/SUP], Yan Gao[SUP] 4 [/SUP], Xiang Fang[SUP] 3 [/SUP], Yao Zhong[SUP] 3 [/SUP], Meihua Wang[SUP] 3 [/SUP], Quan Wang[SUP] 5 [/SUP], Zihe Rao[SUP] 6 [/SUP], Peng Gong[SUP] 7 [/SUP]
Affiliations
- PMID: 34653416
- DOI: 10.1016/j.celrep.2021.109882
Abstract
Remdesivir (RDV), a nucleotide analog with broad-spectrum features, has exhibited effectiveness in COVID-19 treatment. However, the precise working mechanism of RDV when targeting the viral RNA-dependent RNA polymerase (RdRP) has not been fully elucidated. Here, we solve a 3.0-Å structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RdRP elongation complex (EC) and assess RDV intervention in polymerase elongation phase. Although RDV could induce an "i+3" delayed termination in meta-stable complexes, only pausing and subsequent elongation are observed in the EC. A comparative investigation using an enterovirus RdRP further confirms similar delayed intervention and demonstrates that steric hindrance of the RDV-characteristic 1'-cyano at the -4 position is responsible for the "i+3" intervention, although two representative Flaviviridae RdRPs do not exhibit similar behavior. A comparison of representative viral RdRP catalytic complex structures indicates that the product RNA backbone encounters highly conserved structural elements, highlighting the broad-spectrum intervention potential of 1'-modified nucleotide analogs in anti-RNA virus drug development.
Keywords: RNA-dependent RNA polymerase; SARS-CoV-2; broad-spectrum; elongation complex; remdesivir.